What's Happening?
Anixa Biosciences has announced that Cheryl Cox, Operations Director at Moffitt Cancer Center, will present their ovarian cancer CAR-T therapy at the International Society for Cell & Gene Therapy 2026
Annual Meeting. The presentation will cover the design and objectives of Anixa's ongoing Phase 1 clinical trial of lira-cel, a CAR-T therapy targeting the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer. The trial is enrolling women who have progressed after at least two prior therapies. The conference will gather global experts to discuss advances in cell and gene therapy, including gene editing and clinical translation.
Why It's Important?
The presentation of Anixa's CAR-T therapy at a major international conference highlights the potential of this innovative treatment for recurrent ovarian cancer. By targeting FSHR, which is selectively expressed on ovarian cells and certain cancer cells, lira-cel offers a novel approach to treating this challenging disease. The therapy's development in collaboration with Moffitt Cancer Center underscores the importance of partnerships between biotech companies and research institutions in advancing cancer treatment. Success in this trial could lead to new therapeutic options for patients with limited treatment choices, potentially improving survival rates and quality of life.
What's Next?
As the Phase 1 trial progresses, Anixa will continue to monitor the safety and efficacy of lira-cel in enrolled patients. Positive results could pave the way for larger clinical trials and eventual regulatory approval. The company may also explore expanding the use of CAR-T technology to other types of cancer, leveraging its collaboration with Moffitt Cancer Center. The upcoming presentation at the ISCT Annual Meeting will provide an opportunity for Anixa to engage with the global scientific community, gather feedback, and explore potential partnerships for further development and commercialization.
